Shop by goal

  • Metabolic Research
  • GH-Axis Research
  • Muscle & IGF Research
  • Tissue and Cellular Models
  • Regenerative Research
  • Cellular Senescence Research
  • Cognitive Research
  • Multi-Compound Blends
  • Accessories
  • All compounds →

    • Popular compounds

  • BPC-157
  • TB-500
  • GHK-Cu
  • GLP1-RC-RT
  • GLP1-RC-SM
  • Ipamorelin
  • All bestsellers →

    • Research resources

  • Research Glossary
  • Peptide Guides
  • Delivery Guide
  • Track Order

    • Recently viewed

  • Peptide 101
  • Research Areas
  • Peptide Blog
  • Community Forum
  • Crypto Blog
  • Research Glossary
  • Reconstitution Calculator
  • Peptide Tracker
  • Research Protocol Tools
  • Peptide Guides
  • Sign In
  • Create Account
  • Track My Order
  • Refer a Friend
  • My Account
  • My Orders
  • My Referrals
  • Log Out
    • How-to guides

    Research comparison

    Liraglutide vs Retatrutide

    Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

    Updated August 2026 Research use only

    LIRAGLUTIDE

    Liraglutide

    GLP-1

    GLP-1R

    GLP1-RC-RT

    Retatrutide

    Triple receptor agonist

    GLP-1R · GIPR · GCGR

    Key research differences

    Liraglutide Retatrutide Receptor profile GLP-1R GLP-1R · GIPR · GCGR Development status Approved therapeutic molecule Investigational Published half-life 13 h ~6.0 days (144 h) Research distinction Shorter-acting GLP-1R agonism Adds glucagon receptor agonism

    Published research parameters

    Liraglutide Saxenda, Victoza Retatrutide LY3437943 View Retatrutide → Receptor profile GLP-1R GLP-1R · GIPR · GCGR Class GLP-1 Triple receptor agonist Plasma half-life 13 h ~6.0 days (144 h) Time to Cmax 11 h 36 h Development status Approved therapeutic molecule Investigational Study context Regulatory label PK Peer-reviewed human PK Primary publications FDA Saxenda USPI — half-life ~13 h (2023) Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023) Summary Short-acting GLP-1 receptor agonist. Once-daily subcutaneous. Weekly dose escalation reduces nausea. Triple GIP / GLP-1 / glucagon receptor agonist. Phase 3 investigational — research use only. View published study parameters Liraglutide Saxenda, Victoza Retatrutide LY3437943 View Retatrutide → Route in published studies Subcutaneous Subcutaneous Published study interval Once daily Once weekly Published dose range 0.6–3 mg 2–12 mg Published study regimen 0.6 → 1.2 → 1.8 → 2.4 → 3 mg 2 → 4 → 6 → 8 → 12 mg

    Source references

    FDA Saxenda USPI — half-life ~13 h

    FDA prescribing information · 2023

    FDA Saxenda USPI — half-life ~13 h (2023)

    Pi-Sunyer X et al.

    New England Journal of Medicine · 2015

    Pi-Sunyer X et al., NEJM 373:11 (2015)

    Jastreboff AM et al.

    New England Journal of Medicine · 2023

    Jastreboff AM et al., NEJM 389:514 (Phase 2 results) (2023)

    Rosenstock J et al.

    The Lancet · 2023

    Rosenstock J et al., Lancet 402:529 (titration arms) (2023)

    Frequently asked questions

    What is the difference between Liraglutide and Retatrutide? Which has a longer half-life, Liraglutide or Retatrutide? How often is each compound dosed in the research literature? Can you buy Liraglutide and Retatrutide for research use?

    Continue researching

    Research guides, current certificates and related research for Liraglutide and Retatrutide. Research use only.

  • Research guide Retatrutide research guide Published experimental work characterises agonist activity across GLP-1R, GIPR and GCGR, with structural modifications investigated for… Read the guide →
  • Analytical evidence View the Retatrutide COA Current batch purity and identity testing, 2026-07-24. View the COA →
  • Related research Is Retatrutide Safe? What the Research and the Safety Warnings Actually Show After 2026 news reports of retatrutide ("reta") being sold online despite its unapproved status, what the research actually shows on… Read the article →
  • Compare Compare Retatrutide and Semaglutide Retatrutide vs Semaglutide: mechanism, receptor profile and specifications side by side. Compare →

    • Continue research

    ← Compare other compounds

    PRECISION. PURITY. PERFORMANCE.

    Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

    Shop

  • All research compounds
  • Price list
  • Where to buy peptides
  • Compare compounds
  • Compare vial sizes
  • Affiliate programme

    • Research

  • Peptide 101
  • Published COAs
  • Research areas
  • Research blog
  • How-to guides
  • Peptide guides
  • Research glossary

    • Support

  • Track your order
  • Contact us
  • Shipping & delivery
  • International shipping
  • FAQ
  • Community forum
  • Refund policy

    • Ways to Pay

  • Google Pay
  • Apple Pay
  • Venmo
  • Cryptocurrency
  • Crypto wallets
  • Cash App
  • Card payments
  • Bank transfer (SEPA)
  • Paying with crypto
  • Live crypto prices

    • Shop by goal

  • Metabolic Research
  • GH-Axis Research
  • Muscle & IGF Research
  • Tissue and Cellular Models
  • Regenerative Research
  • Cellular Senescence Research
  • Cognitive Research
  • Multi-Compound Blends
  • Accessories

    • Shop by compound

  • BPC-157
  • TB-500
  • GHK-Cu
  • Tesamorelin
  • Retatrutide
  • Semaglutide
  • Tirzepatide
  • CJC-1295 (without DAC)
  • All compounds →

    • Shop by region

  • United Kingdom
  • United States
  • Australia
  • Canada
  • Canada (FR)
  • Ireland
  • Northern Ireland
  • Malta
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Portugal
  • Greece
  • Austria
  • Poland
  • Sweden
  • Finland
  • Denmark
  • Norway
  • Croatia
  • Slovakia
  • Slovenia
  • Estonia
  • Latvia
  • Lithuania
  • Czechia
  • Hungary
  • Romania
  • Bulgaria
  • Belgium
  • Belgium (FR)
  • Luxembourg
  • Deutsch
  • Ελληνικά
  • Español
  • Français
  • Italiano

    • Research use only - all claims made on this site are for testing and research use only. Purchasers must be 21 years of age or older.

    All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.

    Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

    Principal office: 1712 Pioneer Ave., Ste. 500, Cheyenne, WY 82001, USA

    © 2026 New-U Research Compounds · new-u.io

    Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

    © 2026 New-U Research Compounds · new-u.io — Copyright held with Hilxera Distribution Services LLC. All rights reserved.